Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Protara Therapeutics, Inc. | f10k_031820p.htm |
| EX-32.1 - EXHIBIT 32.1 - Protara Therapeutics, Inc. | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - Protara Therapeutics, Inc. | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - Protara Therapeutics, Inc. | exh_311.htm |
| EX-21.1 - EXHIBIT 21.1 - Protara Therapeutics, Inc. | exh_211.htm |
| EX-10.36 - EXHIBIT 10.36 - Protara Therapeutics, Inc. | exh_1036.htm |
| EX-10.30 - EXHIBIT 10.30 - Protara Therapeutics, Inc. | exh_1030.htm |
| EX-10.29 - EXHIBIT 10.29 - Protara Therapeutics, Inc. | exh_1029.htm |
| EX-10.25 - EXHIBIT 10.25 - Protara Therapeutics, Inc. | exh_1025.htm |
| EX-4.3 - EXHIBIT 4.3 - Protara Therapeutics, Inc. | exh_43.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-236173) of ArTara Therapeutics, Inc., |
| (2) | Registration Statement (Form S-8 No. 333-235918) pertaining to the Proteon Therapeutics, Inc. Amended and Restated 2014 Equity Incentive Plan, as amended ArTara Subsidiary, Inc. 2017 Equity Incentive Plan., |
| (3) | Registration Statement (From S-8 333-229123) pertaining to the Amended and Restated 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan of Proteon Therapeutics, Inc, |
| (4) | Proteon Therapeutics, Inc. Form S-8 Registration Statement (File No. 333-222415) pertaining to the Amended and Restated 2014 Equity Incentive Plan and 2014 Employee Stock Purchase Plan of Proteon Therapeutics, Inc, and |
| (5) | Proteon Therapeutics, Inc. Form S-8 Registration Statement (File No. 333-200587) pertaining to the 2014 Equity Incentive Plan, 2014 Employee Stock Purchase Plan, and Amended and Restated 2006 Equity Inventive Plan of Proteon Therapeutics, Inc; |
of our reports dated March 19, 2020, with respect to the consolidated financial statements of Proteon Therapeutics, Inc. included in this Annual Report (Form 10-K) of ArTara Therapeutics, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 19, 2020